Published in J Clin Invest on November 01, 2002
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskelet Disord (2011) 1.37
Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. J Korean Med Sci (2007) 0.89
Bisphosphonate treatment in the oim mouse model alters bone modeling during growth. J Biomech (2008) 0.87
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child (2006) 0.86
The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta. Orthop Rev (Pavia) (2012) 0.84
Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta. J Child Orthop (2011) 0.80
Conservative versus surgical treatment of osteogenesis imperfecta: a retrospective analysis of 29 patients. Clin Cases Miner Bone Metab (2012) 0.75
Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions. Eur J Pediatr (2004) 0.75
Genetic heterogeneity in osteogenesis imperfecta. J Med Genet (1979) 12.51
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med (1998) 3.66
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res (2000) 2.74
Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res (2002) 2.56
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child (2002) 1.65
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest (2002) 1.59
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone (2001) 1.32
Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J Bone Miner Res (2001) 1.25